Literature DB >> 9040459

Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A.

U Benelli1, J R Ross, M Nardi, G K Klintworth.   

Abstract

PURPOSE: Neovascularization of the cornea occurs in numerous pathologic states causing decreased visual acuity and blindness and is a major complication of corneal allotransplantation. The purpose of this study was to investigate the effect of topical and systemic cyclosporin A (CsA) on corneal angiogenesis induced by xenotransplantation or by chemical cauterization. The subcutaneous disc angiogenesis system (DAS) also was used to study the effects of CsA on angiogenesis in a nonocular site.
METHODS: Corneal angiogenesis was provoked by either xenotransplantation or chemical cautery. Rats from experiments using both of these models were subdivided into four treatment groups. Topical treatment was administered by using 4% CsA eye drops or vehicle (castor oil) four times daily for 10 days. Systemic therapy consisted of daily (5 mg/kg per day) subcutaneous injections of CsA or vehicle. In the DAS experiments, rats received CsA or vehicle systemically or intradisc. The amount of neovascularization was quantitated by digital image analysis in corneal flat preparations and sections of discs.
RESULTS: Rats that received xenografts or cautery manifested less corneal neovascularization than did control animals after topical of subcutaneous CsA treatment. CsA also enhanced the survival of corneal xenografts. A difference between CsA and vehicle-treated animals in the DAS experiments was not detected.
CONCLUSIONS: CsA effectively retards the growth of new vessels in the cornea after xenotransplantation or chemical cauterization and prolongs xenograft survival. However, CsA does not suppress angiogenesis in all systems, because it was ineffective in blocking vessel growth in the subcutaneous DAS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9040459

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  20 in total

1.  Curcumin nanoparticles inhibit corneal neovascularization.

Authors:  Nirparaj Pradhan; Rajdeep Guha; Sushovan Chowdhury; Sudip Nandi; Aditya Konar; Sarbani Hazra
Journal:  J Mol Med (Berl)       Date:  2015-04-17       Impact factor: 4.599

Review 2.  Clinical correlates of common corneal neovascular diseases: a literature review.

Authors:  Nizar Saleh Abdelfattah; Mohamed Amgad; Amira A Zayed; Hamdy Salem; Ahmed E Elkhanany; Heba Hussein; Nawal Abd El-Baky
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

3.  A calcineurin-independent mechanism of angiogenesis inhibition by a nonimmunosuppressive cyclosporin A analog.

Authors:  Benjamin A Nacev; Woon-Kai Low; Zhennian Huang; Tina T Su; Zhuang Su; Hisham Alkuraya; Dan Kasuga; Woong Sun; Mario Träger; Manfred Braun; Gunter Fischer; Kang Zhang; Jun O Liu
Journal:  J Pharmacol Exp Ther       Date:  2011-05-11       Impact factor: 4.030

4.  Topical cyclosporin stimulates neovascularization in resolving sterile rheumatoid central corneal ulcers.

Authors:  J D Gottsch; E K Akpek
Journal:  Trans Am Ophthalmol Soc       Date:  2000

5.  Inhibitory effects of topical cyclosporine A 0.05% on immune-mediated corneal neovascularization in rabbits.

Authors:  Yasin Yücel Bucak; Mesut Erdurmus; Elçin Hakan Terzi; Aysel Kükner; Serdal Çelebi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-09-19       Impact factor: 3.117

6.  The effect of bevacizumab on corneal neovascularization in rabbits.

Authors:  Wung-Jae Kim; Hee-Ok Jeong; Sung-Kun Chung
Journal:  Korean J Ophthalmol       Date:  2010-08-03

Review 7.  Current and Upcoming Therapies for Ocular Surface Chemical Injuries.

Authors:  Alireza Baradaran-Rafii; Medi Eslani; Zeeshan Haq; Ebrahim Shirzadeh; Michael J Huvard; Ali R Djalilian
Journal:  Ocul Surf       Date:  2016-09-17       Impact factor: 5.033

8.  Regression of aggressive corneal vascularization after photodynamic therapy, subconjunctival Avastin injections and topical cyclosporin-A 1% drops: A case report.

Authors:  Omar M Kirat; Hassan A Al-Dhibi
Journal:  Saudi J Ophthalmol       Date:  2010-05-27

9.  Comparison of the inhibitory effect of different doses of subconjunctival bevacizumab application in an experimental model of corneal neovascularization.

Authors:  Burak Ulas; Rana Altan-Yaycioglu; Nebil Bal
Journal:  Int J Ophthalmol       Date:  2018-07-18       Impact factor: 1.779

10.  Short-term Efficacy of Topical Immunosuppressive Agents on the Survival of Cultivated Allo-Conjunctival Equivalents.

Authors:  Young Joo Shin; Mee Kum Kim; Joo Youn Oh; Won Ryang Wee; Jin Hak Lee; Jung Hwa Ko; Hyun Ju Lee; Jae Lim Lee; Byung Moo Min; Young Suk Sohn
Journal:  Korean J Ophthalmol       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.